Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises

ARS Pharmaceuticals beat Q4 2025 expectations with EPS of -$0.41 versus -$0.4246 consensus (≈+3.44% surprise) and revenue of $28.1M vs $26.9M forecast (+4.46%), driving a premarket share rise of +1.66% to $9.21. Full-year revenue totaled $84.3M (U.S. net product revenue $72.2M), gross margin ~60%, cash and short-term investments ~$245M, but SG&A remains elevated at $230.1M and shares are down ~22% YTD in 2026. Management plans to expand the sales force from 106 to 150 (funded by reallocation, not higher SG&A), prioritize reducing prior-authorizations and payer coverage, and expects continued commercial ramp with refill dynamics emerging in late 2026–2027.

Analysis

Neffy’s commercial path is being shaped less by clinical differentiation and more by workflow and payer mechanics — the critical inflection is embedding the product into electronic renewal and PBM formularies rather than incremental DTC awareness. That implies a lumpy, calendar-driven revenue cadence: payer decisions and school-year seasonality will create concentrated upside windows (months), while installed-base expirations generate a multi-quarter refill tail (quarters→year).

The company’s reallocation of marketing dollars into field coverage is a classic early-launch optimization: higher frequency calls in top-decile practices should raise share in the short run, but it increases execution risk if the company simultaneously underfunds top-of-funnel outreach that seeds digital conversion channels. If payer wins lag or prior-authorization friction persists, the sales-force investment will produce lower ROI and force renewed DTC spend or deeper discounting to maintain uptake.

Second-order beneficiaries include vendors that manage e-prescribing, patient-assist virtual clinics, and analytics firms used to demonstrate equivalence in real-world settings; these groups become leverage points for accelerating renewals without in-person visits. Key timing windows to watch are mid-year PBM formulary moves and the back-to-school seasonal demand spike, plus the Phase 2b readout cadence later this year that could re-rate optionality into the stock if positive.

Key Decisions for Investors

• Event-driven directional (SPRY): Buy a defined-risk call spread (6–12 month expiry) into confirmed PBM formulary wins (primary trigger: unrestricted placement by the large national PBM). Rationale: asymmetric upside from accelerating electronic renewals; downside limited to premium paid if prior-auth friction persists. Target reward ≈ 2–3x worst-case premium, exit on 40–60% realized gains or on missed formulary decision.
• Pair trade (long SPRY / short incumbent auto‑injector): Establish a small long SPRY vs short a legacy auto‑injector incumbent (equal dollar delta) over 6–12 months to isolate share-shift into renewal workflows. Rationale: captures operational share gains if neffy wins workflow placement; hedge reduces market beta. Risk: incumbents win aggressive contracting causing both to move; keep position size small and set a 15% stop-loss on the pair.
• Tactical long on data/solutions (IQV): Add exposure to the RWE/analytics provider over a 12–24 month horizon as payer negotiations and real‑world evidence needs increase. Rationale: monetization of claims and outcomes data rises with new product launches that require conversion evidence. Manage position by trimming on >25% rally and monitor macro spending on pharma services.
• Protective hedge for equity holders: If owning SPRY, buy 4–6 month OTM puts as insurance across the key summer BP M decision window and back‑to‑school season. Rationale: limits downside from a negative formulary or inventory squeeze while retaining upside into refill-driven revenue later in the year.